Warfarin
1. Pregnancy Evidence & Regulatory Labeling
FDA Pregnancy and Lactation Labeling Rule (PLLR 8.1) & EMA SmPC Section 4.6
Clinical Risk Summary
FDA Boxed Warning & Strict Contraindication (Except in mechanical heart valves with high thromboembolic risk). First-trimester exposure between weeks 6 and 12 causes Fetal Warfarin Syndrome (nasal hypoplasia, chondrodysplasia punctata / stippled epiphyses, limb hypoplasia). Exposure during the 2nd and 3rd trimesters causes central nervous system defects (microcephaly, optic atrophy, blindness, intracranial hemorrhage) and fetal demise.
Human Pregnancy Experience & Clinical Studies
Extensive published literature shows a 5-10% rate of embryopathy with 1st trimester exposure and significant risk of fatal fetal intracranial bleeding near term.
Animal Reproductive & Developmental Toxicity Data
Animal studies showed embryolethality and severe teratogenicity in multiple species.
Clinical Considerations for Prescribers
Low Molecular Weight Heparins (LMWHs, e.g., Enoxaparin) are the first-line anticoagulants of choice in pregnancy because they do not cross the placenta.
Placental Transfer
Small lipophilic molecule that crosses the placenta freely into fetal circulation.
Regulatory Warnings & Contraindications
FDA Boxed Warning: This medication carries an official Boxed Warning regarding embryo-fetal toxicity or pregnancy-related adverse outcomes.
Contraindicated in pregnancy due to severe embryopathy and fatal fetal hemorrhage risks.
2. Lactation & Breastfeeding Safety
NIH / NLM LactMed® Database & FDA Labeling Section 8.2
Summary of Use during Lactation
Warfarin is considered safe and compatible with breastfeeding by NIH LactMed and the AAP. Warfarin is not detected in breast milk in measurable quantities and does not affect the infant's prothrombin time.
Drug Levels in Breast Milk & Relative Infant Dose
Undetectable in human breast milk (<0.025 mg/L).
Effects in Breastfed Infants & Monitored Signs
No coagulation changes or bleeding observed in breastfed infants.
Effects on Lactation & Milk Production
No effect on milk production.
Alternate Medications with Established Lactation Data
4. Regulatory Source Provenance & Comparison
Direct attribution to official regulatory documents without synthesized consensus
| Regulatory Organization | Jurisdiction | Document / Framework | Effective Date | Official Source Link |
|---|---|---|---|---|
|
National Institutes of Health (NIH) / NLM
LactMed® Database (Drugs and Lactation)
|
United States / Global | evidence_monograph | 2026-08-01 | Official Record |